Navigation Links
Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
Date:10/20/2009

EAST RUTHERFORD, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) announced today that it won the Silver Innovation Award at the 2009 CPhI Event for its Continuous-Flow Microwave-Assisted Organic Synthesis (CFMAOS) technology. The award was accepted by Dr. Jayne E. Muir (Market Research & New Technologies - Europe), who presented the technology to a panel of judges at this important pharmaceutical ingredients exhibition in Madrid, Spain on October 13, 2009.

The CPhI Innovation Awards give companies the chance to showcase the best of their R&D efforts and are widely recognized as premier awards in the field of international pharmaceutical manufacturing. This year had a particularly strong number and quality of entries and the six shortlisted companies spanned a wide range of subjects, from biopolymers to colors and coatings. On accepting the award, Dr. Muir said, "The area of flow chemistry is very exciting at the moment, and we were pleased with the interest and number of questions about the CaMWave(TM) technology following the presentation and throughout CPhI."

The CF-MAOS technology represents a dual technological breakthrough, allowing both the scale-up of microwave-assisted chemistry and the handling of heterogeneous mixtures in continuous-flow. This new technology will finally bring the benefits of both technologies out of the laboratory and into production. The CaMWave(TM) KiloLAB flow reactor is capable of manufacturing in excess of 20 kilograms of product per day, and larger reactors will generate more than one hundred metric tons of product per year. This versatile technology facilitates faster, cleaner, more reliable reactions, leading to improved productivity and lower manufacturing costs.

If you would like to inquire further about this technology, please contact Dr. Jayne E. Muir at +44 (0)1223 237527 or jayne.muir@cambrex.com.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including active pharmaceutical ingredients ("API"), advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals. For more information, please visit www.cambrex.com.

SOURCE Cambrex Corporation


'/>"/>
SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
11. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Microplate Instrumentation ... ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
(Date:3/23/2017)... The key factors driving the growth ... accelerating economic growth and increasing healthcare expenditure. Some of the ... expectancy of ESRD patients, rising demand for home PD treatment ... of the market is hindered by high treatment costs and ... ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... Infectious disease affects billions of people ... States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting Infection” ... strategies for the healthcare community to help decrease the number of completely preventable ...
(Date:3/24/2017)... ... 2017 , ... The iaedp Foundation, the premier provider of educational programs and ... from the full spectrum of disordered eating, announced today that the 2017 Symposium set ... 50 states and several countries converged on the Green Valley Resort in Las Vegas. ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... announce that they are now offering treatments for sleep apnea and TMJ at ... offices. Sleep apnea , specifically the obstructive type, is increasingly being treated ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... year of enhancements, upgrading their training and leads programs. , In February, 2017, ... for elite sales agents, Performance Partners is designed to teach how to maximize ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion ... real people of God in congregations across the United States. “The Communion ... ordained in 1964 who has served congregations in seven states throughout his long ...
Breaking Medicine News(10 mins):